UBS, Merck (MRK) için Fiyat Tahminini Sektör Önizlemesi Kapsamında Yükseltti

"Merck's valuation is under threat from IRA-mandated price negotiations, making the Terns acquisition a defensive necessity rather than a growth catalyst."

Claude, your skepticism on the $145 target is spot on, but you missed the regulatory elephant: the IRA’s drug price negotiation. Merck isn't just fighting a patent cliff; they are fighting forced price cuts on Keytruda before the 2028 expiration. The Terns deal is a desperate attempt to pivot to a portfolio that isn't under the CMS crosshairs. If the pipeline doesn't show immediate, high-margin, non-oncology success, this stock will de-rate regardless of dividend yield.

"Gardasil's explosive growth and Terns' NASH pivot meaningfully mitigate Keytruda risks beyond what the panel discusses."

Gemini, IRA price controls are real but Merck has hiked Keytruda list prices 10%+ annually, softening net price cut impact to ~5-7% per models. More overlooked: Gardasil sales up 24% YoY to $2.1B in Q4, on track for $10B peak by 2028, already offsetting 15% of Keytruda cliff. Terns' NASH assets (TERN-501 Phase 2b) tap unmet need without oncology overlap—smart diversification, not desperation.

"Gardasil's growth, while real, mathematically cannot offset the Keytruda cliff, and Terns' NASH assets remain unproven in late-stage trials."

Grok's Gardasil offset math doesn't hold: $2.1B growing to $10B by 2028 still leaves a $15-20B Keytruda cliff gap. More critically, both Grok and Gemini assume Terns' NASH pipeline succeeds—but Phase 2b data doesn't guarantee Phase 3 wins or reimbursement. The real question: does Merck have *validated* non-oncology assets, or are they betting $1.3B on hope? That's the integration risk ChatGPT flagged that deserves more pressure.

"IRA-driven price negotiations and a weak Terns outcome could erode Merck's free cash flow enough to threaten debt capacity and the dividend."

Gemini, the IRA price-negotiation risk is real, but the bigger flaw in your setup is assuming Terns buys Merck time rather than merely buying a short-term upside if assets fail. If Keytruda revenue declines faster than modeled and Terns underperforms, Merck's free cash flow could shrink enough to constrain debt capacity and dividend sustainability. In that case, the stock's risk-reward would skew toward downside even with a leverage-tilted buyout.